Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02331056
Other study ID # 2014-06-053-002
Secondary ID
Status Completed
Phase N/A
First received December 15, 2014
Last updated October 6, 2016
Start date July 2014
Est. completion date June 2015

Study information

Verified date October 2016
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority South Korea: Institutional Review Board
Study type Observational [Patient Registry]

Clinical Trial Summary

There are some risks of pulmonary edema in patients undergoing pulmonary lobectomy with one lung ventilation. The overloading of fluid administration could be related to the development of pulmonary edema in patents after thoracic surgery. But fluid restriction may cause major organ hypoperfusion during the surgery. The purpose of this study is to evaluate the ability of stroke volume variation as an indicator for a fluid responsiveness in patient who receives pulmonary lobectomy via thoracotomy.


Description:

Perioperative fluid management during thoracic surgery is a significantly important, because it is quite difficult to prevent pulmonary edema due to the fluid overload and compromise perfusion of vital organ. So, it is essential to maintain optimal organ perfusion by appropriate fluid management during thoracic surgery. Stroke volume variation (SVV) is derived from pulse contour analysis and it is known that SVV ≥12~15% correlate with fluid responsiveness, defined as a significant increase in cardiac output with fluid loading, dung two-lung ventilation. It is a parameter derived from changes in stroke volume (SV) that is according to the heart-lung interaction during mechanical ventilation. positive pressure ventilation induces cyclic changes in left ventricular SV that are related mainly to the expiratory decrease in right ventricular filling and ejection. This is a reflected by variations in the SV. However both ventilator issues, such as tidal volume, PEEP, chest and lung condition, and the cardiovascular condition, such as heart rate, rhythm, ventricular function, cardiac afterload, arterial compliance may affect SVV. Recently some studies reported that SVV could predict fluid responsiveness in mechanically ventilated patients under various conditions. But it is still unclear whether SVV could predict fluid responsiveness during one lung ventilation with the chest open via a thoracotomy. During one-lung ventilation, the shunted blood flow through the non-ventilated-lung dose not contribute to the generation of SVV. And with the chest opening by thoracotomy, the pressure generated by ventilator would not be transmitted to the pulmonary vessels but rather to the atmosphere. So, the purpose of this study is to evaluate the ability of SVV as an indicator a fluid responsiveness particularly in patients undergoing one-lung ventilation with thoracotomy and to found the optimal threshold value of SVV for fluid management during thoracic surgery.


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date June 2015
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

- The patients scheduled for pulmonary lobectomy with one lung ventilation by lung cancer, nodule, or pulmonary tuberculosis under thoracoscopy or thoracotomy in our hospital

Exclusion Criteria:

- The patients with known cardiac disease include arrythmia

- American society of anesthesia physical status III, IV, V

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Intervention

Other:
fluid loading
Fluid loading at defined period 500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records.
Procedure:
thoracoscopic pulmonary lobectomy
the patient group for scheduled thoracoscopic pulmonary lobectomy
thoracotomy
the patient group for scheduled open pulmonary lobectomy

Locations

Country Name City State
Korea, Republic of Samsung medical center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of Participants with Adverse Events (pulmonary complication) after surgery check chest x-ray It's the routine follow up after lobectomy. participants will be followed for the duration of hospital stay, an expected average of 1 week No
Other Number of Participants with Adverse Events (compromise perfusion of vital organ ) check perioperative urine output, and check post op serum creatine participants will be followed for the duration of hospital stay, an expected average of 1 week No
Primary Changes from baseline in SVV, SVI after fluid loading we are going to measure the SVV, SVI before and after fluid loading. Fluid responders were defined as patients demonstrating an increase in SVI = 10% and non-responders as patients whose SVI changed < 10%. Receiver operating characteristic (ROC) curves were generated for SVV of each group (responders and non responders). Threshold value of SVV was determined by considering values that yielded the greatest sensitivity and specificity from ROC curve 20min after thorax open and immediate after fluid loading for 30min No
See also
  Status Clinical Trial Phase
Completed NCT02736864 - Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae N/A
Not yet recruiting NCT04055441 - A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
Completed NCT02349841 - Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis Phase 2
Completed NCT01927159 - Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers Phase 1
Active, not recruiting NCT01691534 - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) Phase 2
Completed NCT00803322 - Improving Community Based Tuberculosis Care in Ethiopia Phase 4
Completed NCT00834353 - Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis N/A
Withdrawn NCT03277742 - Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz N/A
Completed NCT00057434 - Vitamin A Therapy for Tuberculosis Phase 3
Recruiting NCT06127641 - Rehabilitation of People With Post-tuberculosis Lung Disease N/A
Recruiting NCT06058299 - Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis Phase 2
Completed NCT04550832 - PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) Phase 2
Completed NCT02912832 - Prospective Assessment of TBDx Feasibility N/A
Completed NCT01215851 - Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) Phase 2
Recruiting NCT01503099 - Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease N/A
Completed NCT04608955 - Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 Phase 2
Recruiting NCT05046366 - Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
Completed NCT05896930 - Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis Phase 2
Completed NCT02279875 - A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) Phase 2
Completed NCT02554318 - Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia N/A